Background: Recent evidence indicates that Gram-negative bacterial pathogens, the most common of which are\r\nPseudomonas spp., Enterobacteriaceae, and Acinetobacter baumannii, are frequent causes of hospital-acquired\r\ninfections. This study aims to evaluate the in vitro activity of doripenem and comparator carbapenem antibiotics\r\nagainst Gram-negative clinical isolates collected from COMParative Activity of Carbapenem Testing (COMPACT)\r\nstudy centres in Turkey.\r\nMethods: Ten centres in Turkey were invited to submit Pseudomonas aeruginosa, Enterobacteriaceae, and other\r\nGram-negative isolates from intensive care unit (ICU)/non-ICU patients with complicated intra-abdominal infections,\r\nbloodstream infections, or nosocomial pneumonia, including ventilator-associated pneumonia, between May and\r\nOctober 2008. Susceptibility was determined by each centre using E-test. A central laboratory performed species\r\nconfirmation as well as limited susceptibility and quality-control testing.\r\nResults: Five hundred and ninety six isolates were collected. MIC90 values for doripenem, meropenem, and\r\nimipenem, respectively, were 32, = 64, and = 64 mg/L against Pseudomonas spp.; 0.12, 0.12, and 0.5 mg/L against\r\nEnterobacteriaceae; and = 64 mg/L for each against other Gram-negative isolates. In determining the susceptibility\r\nof hospital isolates of selected Gram-negative pathogens to doripenem, imipenem, and meropenem, we found\r\nthat against all pathogens combined, the MIC90 for ICU compared with non-ICU isolates was higher.\r\nConclusions: Doripenem showed similar or slightly better activity than meropenem and better activity than\r\nimipenem against the Gram-negative pathogens collected in Turkey.
Loading....